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Abstract
This report intends to assess the implications of the
Trade-related Aspects of Intellectual Property Rights
(TRIPS) and the Convention on Biological Diversity (CBD)
for coastal communities’ access to, and control over,
aquatic biodiversity. To this end, it reviews marine
biodiversity, coastal communities’ traditional ecological
knowledge systems (TEKS) and the biodiversity they
have conserved, and the industrial exploitation of marine
genetic resources; it then analyzes TRIPS and the CBD as
applied to marine biodiversity, and the implications of
TRIPS and the CBD for both coastal States and fishing
communities’ access to marine resources, control over
their knowledge, and share of the benefits; lastly, it ends
with some proposals for further research and action by the
International Collective in Support of Fishworkers (ICSF).
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1. Foreword
Over the past few years, the matter of who controls biodiversity and
associated knowledge has been high on the agenda of international
development and environmental discourse. Discussions on this issue
have been fuelled by both the ever-increasing restrictions on farmers’
rights to save seeds and public outrage on a pandemic of biopiracy—
the unauthorized appropriation of the plants, knowledge and even
the cells of indigenous peoples and local communities the world over.
Coastal communities, however, have been largely marginalized from
these debates.
This report is the outcome of a one-month desk research on the
implications of the international legal framework regulating control
over biodiversity, the Convention on Biological Diversity (CBD) and the
Trade-related Aspects of Intellectual Property Rights (TRIPS) Agreement
of the World Trade Organization (WTO). The research focuses on the
medicinal use of marine biodiversity, both in traditional ecological
knowledge systems (TEKS) and Western industry, and in aquaculture.
This research was commissioned by the International Collective in
Support of Fishworkers (ICSF).
2. Control over Biodiversity: A Global Issue
It is difficult to overemphasize the importance of biodiversity—the
variability within living beings and their relationships to one another
and the environment that supports them. Diversity is the key to
the organization of living forms. Within a single species, diversity
spells change: variability allows the species to combine the adaptation
to its current environment with adaptability to new situations. For
ecosystems, diversity spells stability: larger numbers of species result in
more complex flows of energy, matter and information, which, in turn,
tend to make ecosystems more resilient to changes. For life, diversity
spells opportunities; and human beings are no exception to this fact.
In Palaeolithic and modern times alike, from Australia to the
Americas and the Pacific Islands, species extinctions and ecological
havoc have accompanied the waves of expanding human populations
[1]. Established rural cultures, however, have relied on their ecosystems’
biodiversity for food, healing, shelter and clothing—and they have built
their cosmovisions and spirituality around such biodiversity.
Altogether, the intricate interrelationship between nature and culture
is called “biocultural diversity”[2]. Biocultural diversity comprehends
traditional ecological knowledge systems (TEKS), which are (i) systemic,
meaning that any part of the ecosystem is known as it relates to the
whole; (ii) local, meaning that they take as a reference the world the
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cultures inhabit; and (iii) indissoluble from the culture as a whole,
meaning that they cannot be understood on their own.
Since it embeds the strategies of rural peoples to ensure a livelihood
out of their environments, biocultural diversity has not only maintained,
but sometimes even enriched, biological diversity. The sum of
innumerable thousand-year-old interactions among local communities,
indigenous peoples and their crops has yielded hundreds of thousands
of crop varieties and thousands of domestic animal races. Peoples need
only one hundred years to learn how to use the plants of an entirely new
area—and how to preserve and look after the most useful ones [1].
By no means does direct reliance on biodiversity belong to the
past. The world’s poorest rely on biodiversity and TEKS. It is
estimated that about 85 per cent of the population of Africa depend
on traditional medicine for their health care [3] , and 90 per cent of
African crops are grown using farm-saved seed [4]. For the rural poor
in developing countries, access to biodiversity may be the difference
between self-reliance and exclusion. Perhaps even more importantly,
the development of TEKS may be the difference between the rural poor’s
progress and their stagnation.
For industry, biodiversity is a raw material for the pharmaceutical,
natural medicine, seed, ornamentals, pesticides, cosmetics and
industrial biotechnological sectors. In this context, it is often referred to
as genetic resources. A 1999 estimate placed the annual commercial value
of biodiversity for these sectors at between US$500–800 bn [5]. Much
of this value stems from the development of modern biotechnologies,
particularly genetic engineering.1 Such technologies have dramatically
increased the expectations on the use of living organisms and their
parts in industrial processes—as commodities, biofactories, or elements
of production chains. As industry incorporates living beings into
production strategies, it is also ensuring control over them—biodiversity
is being privatized. In the United States of America (US) and the
European Union (EU), industry has strongly promoted, and obtained,
the extension of industrial intellectual property rights (IPRs) to life
forms and their parts (see Box 1). Consequently, the scope of patent
protection has progressively extended from extracts and substances
obtained from living beings, to genes, genetically engineered organisms,
and even organisms claimed to be novel. In the process, the differences
between invention and discovery have been progressively blurred, and,
increasingly, the first to describe something becomes its first owner.
While most of industrial transformation is taking place in developed
countries, biodiversity is concentrated in the tropical belts of the planet,
1Genetic engineering consists in introducing a fragment of deoxyribonucleic acid,
DNA, containing genetic information, into an organism, so that the organism acquires
a new characteristic.
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Box 1
Patents
A patent is a legal claim over an invention that gives the holder
exclusive rights to profit from it for a set number of years. It is
a privilege granted by the State in exchange for the full disclosure
of the invention so that it contributes to society’s knowledge. By
ensuring the inventors a monopoly on the market for their inventions,
patents are supposed to encourage investment in innovation, which,
in the end, is to benefit society as a whole. Patents are a form
of Intellectual Property Rights–IPRs–designed to protect industrial
innovation. Other forms of IPRs include author rights, copyrights,
trade secrets, and plant breeders’ rights.
To be granted a patent, an applicant must be able to prove:
• Novelty: The claim must cover a new idea, not known or used by
anyone before.
• Use: The patent application must explain what the invention is to
be used for and why it is better than existing technologies.
• Inventiveness: It must involve an inventive step that is ‘non-
obvious’.
For a patent to be valid, it must disclose the invention in a way that
allows others skilled in the art to reproduce it—otherwise, the patent
can be withdrawn.
Permission for public use of the invention is granted by paying
the patent holder licence or royalty fees. However, it is the holder’s
privilege to decide whether or not to provide this permission, and
to establish the amount for the royalties. A patent is, therefore, a
compromise between the rights and interests of the inventor and those
of the public.
Historically, the State developed some mechanisms to protect the
public from abusive patent-derived monopolies. Patents were not
allowed in strategic sectors such as medicinals, housing, clothing and
food. Discoveries, ideas and therapeutic methods were excluded from
patent protection. Furthermore, governments introduced compulsory
licensing rules that could force patent holders to license their patented
inventions under given circumstances.
Nevertheless, the history of patent protection is that of a steady
growth of the rights of the inventors—who themselves have evolved
from a majority of private citizens to a majority of privately-owned
corporations lobbying to increase their privileges.
(contd. . . )
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Box 1
Patents (. . . contd)
Patent holders’ rights have grown in three main ways. First,
the scope of patent protection has extended as new industries
have developed. For example, patent claims by the chemical and
pharmaceutical industries led to key decisions in patent offices and
courts that extended to substances already existing in nature.
In the late 1970s and throughout the 1980s, another series of court
decisions in the US established, for the first time, that bacteria, plants
and animals could be patented. a Now, even ideas for business are
being patented [6].
Second, the value of patents for market protection is being
strengthened as IPRs are included in multilateral and bilateral trade
and investment agreements. These agreements, in common, oblige
the signing parties to recognize the patent holders’ rights. TRIPS (see
below) is the most important of such multilateral agreements.
Third, industry has strongly lobbied to limit, as much as possible,
the conditions under which compulsory licensing can be allowed.
Therefore, unless developing countries react, a bioprospector will
soon be able to obtain patents over the use of a marine organism for
the treatment of any disease; have his or her property acknowledged
in the country where the marine organism has been found; and
prevent that country from using any drug obtained from that
organism.
It is often argued that IPRs over genetic resources are not relevant
for local communities because they cannot be used to prevent the
traditional use of such genetic resources. That is, a coastal community
using a fish species for curing an ailment would be able to continue to
do so even if a company were granted a patent on the active principle
in this fish and had its patent enforced in the country of the coastal
community. However, patents do shift the control from the local
innovators to the patent holder. In this hypothetical case, the patent
holder could bar the fishing community from creating a new market
for the fish it uses and from creating a niche export market in any
country where the patent has been granted; also, it could establish
itself as the single purchaser, force an unsustainable fishery to meet
its commercial objectives and later shift to new communities or even
countries.
aRespectively through the US Supreme Court decision in Diamond vs.
Chakraborty (1980), the Patent Office Board of Appeals decision ex parte Allen
(1987).
8
and most of it is found in the territories and waters of developing
countries. Much of this biodiversity has been created, identified,
nurtured or conserved by indigenous peoples and rural communities.
Developed countries have had the time, power and resources to extract
the most interesting genetic resources from developing countries. Often,
they have organized bioprospecting expeditions, which focused on
indigenous peoples and local communities, to extract their knowledge
over biodiversity—when not their own tissues2—only to ignore or
downplay their contribution when filing patents. Such biopiracy is
perhaps the clearest exponent of the violence of the privatization of
biodiversity.
Developing countries overwhelmingly lack the capital, human
resources, technology, knowhow and market access to industrially
exploit their biodiversity on their own. Also, the North’s IPRs bar them
from access to the industrial processes feeding on their biodiversity and
to the final products. As a result, many developing countries have
chosen to use the biodiversity in their territories as an asset to participate
in the benefits arising from their commercialization. Unfortunately,
the alternative route of further strengthening and developing TEKS has
attracted much less attention.
Currently, there are two international legally binding conventions
dealing with control over biodiversity. First to enter in force, the
Convention on Biological Diversity (CBD) acknowledges countries’
sovereign rights over their biodiversity, and it conditions access to
genetic resources to the countries’ prior informed consent and the
fair and equitable sharing of the benefits arising from the industrial
utilization of these resources. Second to enter in force, the Trade-
Related Aspects of Intellectual Property Rights (TRIPS) Agreement of the
World Trade Organization (WTO) forces all WTO members to establish
IPR systems covering all technologies and products, including, to an
unprecedented extend, life forms and their parts. TRIPS was proposed
and drafted by industry and pushed mainly by the US.
Biocultural diversity, the privatization of life, the impact of patents
over TEKS and the implications and contradictions between TRIPS
and the CBD, have led to much political debate within indigenous
peoples, farmers’ organizations, local communities, NGOs, parliaments
and governments in Asia, Latin America and the Caribbean, and parts of
Africa. Nowhere, though, have coastal communities got involved, and
aquatic diversity has virtually been out of these discussions.
2Conceived as a scientific endeavour to study the history of human populations, The
Human Genome Diversity Project intended to collect and ‘immortalize’ human tissue
from 722 human populations, including many indigenous peoples from around the
world. The project raised ethical concerns because it treated these human populations
as objects with no say in the programme implementation and because it gave rise to
the patenting of cell lines obtained from some of these groups’ tissues.
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This report intends to assess the implications of TRIPS and the CBD for
coastal communities’ access to and control over aquatic biodiversity. To
this end, it reviews marine biodiversity, coastal communities’ TEKS and
the biodiversity they have conserved, and the industrial exploitation of
marine genetic resources; it then analyzes TRIPS and the CBD as applied
to marine biodiversity, and the implications of TRIPS and the CBD for
both coastal States and fishing communities’ access to marine resources,
control over their knowledge, and share of the benefits; lastly, it ends
with some proposals for further research and action by the ICSF.
2.1. Marine biodiversity and the 20,000 new substances
Oceans cover 71 per cent of the earth’s surface and account for 90 per
cent of the biosphere, showing that biodiversity is not well captured just
by species numbers. In 1998, ‘only’ 200,000 marine animal species, about
20,000 algae and fewer microorganisms had been described; not very
impressive figures, compared with over 2 mn animal species and 40,000
plants with flowers inhabiting the continents. Marine species, though,
differ much more among each other than their terrestrial equivalents.
Only five out of the 33 existing animal phylum are not represented in
the marine environment, while 13 of them are exclusively marine. As a
result, genetic, biochemical and physiological animal diversity is much
larger in the oceans than on land [7].
Another factor that contributes to marine biodiversity is the
difference in communities contained at different light, temperature,
pressure and food availability conditions. In the open seas, production
is highest in the upper layers—the pelagic environment; less than 1 per
cent of it reaches the ocean bottom.
Until the middle 1900s, it was believed that the abyssal plates at the
sea bottomwere inhabited. Modern bathyscaphs have shown that, while
its total biomass is very low, benthic fauna in abyssal plates is at least as
rich in species, if not more so, as relatively shallow sediments [7].
Marine depths were to deliver another surprise. In 1977, very rich
communities were discovered around vents at marine dorsals, at depths
over 2,500 m, pressures above 25 atmospheres and temperatures above
100 ◦C. These communities are built over the symbiotic association of
chemosynthetic bacteria and animals. These chemosynthetic bacteria
obtain energy out of the oxidation of dihydrogen sulphide instead of
photons.
Later on, it was found that chemosynthesis is quite extended in the
oceans, and, in fact, it uses the energy of the oxidation of methane from
the degradation of organic matter [7]. This challenge of the old belief that
all marine production relied on photosynthesis shows to what extent the
marine environment remains unknown.
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Even the much more accessible pelagic waters have yielded big
surprises. For many years, it was thought that most photosynthesis
in the oceans was carried on by microscopic eucaryotic3. organisms,
phytoplankton. But the world’s most abundant known photosynthetic
organism, the prokaryote4. Prochlorococcus, was only discovered in
1988. In fact, a whole new category of plankton, the picophytoplankton,
has only been known since 1979. Yet, the newly discovered
picophytoplankton accounts for more than 90 per cent of the
ocean photosynthesis, which, in turn, accounts for 50 per cent of
photosynthesis in the planet [8].
The most diverse marine environments are shallow waters close to
the coast. Of the 200,000 marine animals described, 130,000 depend on
rocky or coralline substrates; in comparison, 60,000 live in sediments,
and only a few thousands are planktonic or pelagic. Coral reefs are the
most diverse, complex and productive marine ecosystems. Reefs cover
0.2 per cent of the ocean’s area and yet they provide home to one-third
of all marine fish species, tens of thousands of other species and about
10 per cent of human fish consumption globally [9].
Diversity in coral reefs is also linked to diversity—and the health—
of tropical mangroves and sea grasses, which host the juvenile stages
of many fish species [9]. Diversity in coral reefs is not uniform, being
highest around Indonesia’s waters. Although some developed countries
(including Japan, Australia, the US and France, in its overseas territories)
hold coral reefs, most are located in developing countries [10].
The oceans still keep many secrets; by doing so, they hold the
promise of containing many substances of potential use in different
industries. Bioprospectors seek to tap these substances. Before
reviewing their activities, though, this report will focus on the first
discoverers of what marine (and aquatic) biodiversity may be used for.
2.2. Coastal communities and aquatic biodiversity: knowledge
and uses
For many coastal peoples, their culture, identity and TEKS are
inextricably linked to aquatic biodiversity. Many of them have
developed management systems that, while ensuring the conservation
of their food resources, have allowed for the conservation of fish stocks
and, it can be argued, their surrounding marine environment. Only
recently have such traditional management systems started to receive
the attention and credit they deserve.
3Eucaryote cells have an internal membrane that splits cells into two main
compartments, the nucleus, which contains most of the cell’s genetic material, and the
cytoplasm
4Prokaryotes are unicellular organisms with no nuclear membrane, like bacteria
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Even if—as on land—knowledge on biodiversity has mainly
contributed to coastal peoples’ food security, they have learned to use
it in myriad other ways. One such is its use for healing. For example,
the coastal First Peoples of northwestern America (British Columbia)
have used marine algae in healing and health care. Rockweed (Fucus sp)
was used as a burn medicine, and applied to sores, swellings and eyes.
Also, it was rubbed on the limbs for strengthening them or to alleviate
muscle aches and pains or even paralysis of the legs [11]. Traditional
healing practices in the Maldives rely both on terrestrial plant species
and many marine species of fish, coral and seaweed [12]. Likewise,
northwestern Canada’s handcrafting of anchor lines, fishing lines using
bull kelp (Nereocystis luetkeana), and the weaving of Eleocharis dulcis or
kuta, in Northern Fiji, illustrate the use of marine (and coastal) diversity
in coastal communities’ technologies [11, 13]. More directly related to
food production, TEKS on aquatic biodiversity have also resulted in the
domestication of carp species (see below). The complexity of these
systems may be appalling. In Brazil, a study conducted in Conde, a
coastal city of State of Bahia, to document the traditional zootherapy
knowledge of the Siribinha artisanal fishing community found that this
community uses at least 55 animal species as folk medicine, including
fish (44 per cent), reptile (17 per cent), crustacean (9 per cent), mammal
(7 per cent), bird (5 per cent) echinoderm (5 per cent), annelid (23 per
cent) and amphibian (2 per cent) species [14].
Astonishingly little information about coastal communities’ TEKS on
uses of marine biodiversity other than food is available through the
ordinary information channels on indigenous knowledge and genetic
resources. This paucity partly reflects a lack of a structured corp of
information on these aspects of coastal people’s TEKS in English. In
1998, the traditional use of fish and fish products, wastewater, etc, for
non-food uses accounted for only 71 of the more than 7,500 innovations
and practices compiled by the Honey Bee Database.5 [15] This lack of
available information has little to do, however, with the actual richness
of these thriving TEKS, only 5 per cent of whose wealth is understood
by anthropologists—at least, in Southeast Asia [16]. The example of
Brazil illustrates the wealth untapped by a single focused study in a
single fishing community. Whether these systems can continue to thrive
and develop will depend on many factors, including the industrial
use of marine biodiversity and the priority societies grant to coastal
communities’ control over their resources.
5The Honey Bee Database has been established by the Society for Research and
Initiatives for Sustainable Technologies and Institutions (SRISTI), to scout, spawn,
sustain, disseminate and reward grassroots innovators and experts in traditional,
ecological, technological, educational and institutional knowledge developed by local
communities and individuals without any outside help. Available at: http://www.
sristi.org/honeybee.htm.
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3. Marine Biodiversity and Industry
Just as it happens with local communities, fisheries for food and
reduction purposes are the main form of industrial exploitation of
aquatic biodiversity. Marine diversity is increasingly feeding other
industries, too. On the one hand, many industries are turning to
the sea, expecting that its huge genetic, biochemical and physiologic
diversity will contain useful substances—genetic resources. Three
factors have contributed to this renewed interest, by increasing aquatic
bioprospectors’ competitiveness:
1. the dramatic increase of the costs of introducing new substances
into the market (from pesticides to drugs);
2. the fact that marine exploration technologies have become cheaper
and more sophisticated; and
3. current chemical and genetic screening technologies allowing to
quickly analyze small samples of living beings for active substances.
On the other hand, aquaculture is now prospecting wild fish stocks
to develop more efficient domestic races.
3.1. Marine biodiversity and the pharmaceutical industry
Coral reefs are by far the most favourite hunting grounds for marine
bioprospectors [7]. In a highly dense environment, sessile, soft-bodied
marine invertebrates that lack obvious physical defences have to rely
on toxic substances to keep at bay predators and competitors for space
at bay [17]. Therefore, they are prime candidates to possess bioactive
metabolites—potential drugs.
The interest in the chemicals produced by marine invertebrates is
not new. In the 1970s, Hoffman-La Roche, by then the world’s top
pharmaceutical company, had already started a marine exploration
operation in Australia, around the Great Barrier Reef. It only lasted
two or three years. According to Jose´ Ferna´ndez Souza-Faro, Chief
Executive Officer of PharmaMar, a Spanish company specializing in
marine bioprospecting, Hoffman-La Roche’s failure was due to the
chemical analysis techniques available at the time, which required
“30 kg of every marine invertebrate to be able to isolate enough of
the compound to elucidate their chemical structure yet have enough
to continue to work with” [18]. In 1986, when PharmaMar started
its research, mass spectrometry and nuclear magnetic resonance had
become so sophisticated that it was possible to work with only 1 to 3 kg
of each species. Today, the Australian Institute of Marine Science (AIMS,
another leading marine bioprospector), claims that only 2 g of material
are required to provide extracts for scanning [19]. Marine bioprospecting
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Table 1
Number of marine chemical structures discovered or refined
in 2000 per type of organisms
Group of organisms Chemical structures
Marine Microorganisms 140
Green Algae 8
Brown Algae 10
Red Algae 39
Sponges 316
Coelenterates 193
Bryozoans 7
Molluscs 45
Tunicates (ascidians) 74
Echinoderms 24
Miscellaneous (crustaceans and others) 13
Source: Extracted from Faulkner, J. Marine natural products, Nat. Prod. Rep.,
2002, 19: 1–48
is no Herculean task anymore. In 1998, research on the pharmacology of
marine chemicals (excluding anticancer research) involved investigators
from at least 22 countries [20].6
To date, more than 10,000 marine metabolites have been described. A
review covering the marine natural products literature for the year 2000
described 869 chemical structures that were either discovered or newly
synthesized that year [17]. Table 1 illustrates how bioprospectors cover
all the groups of marine organisms. The high number of structures from
sponges is in line with the fact that these organisms have provided more
marine natural products than any other phylum, due, in part, to their
propensity to produce bioactive metabolites.
In contrast, the number of papers reporting the chemistry of
echinoderms7 is steadily declining. Besides, the historic contribution of
bryozoans as a source of marine chemicals is larger than suggested by
the table.
The pharmaceutical industry puts this large diversity to work.
Research is in progress on antibacterial, anticoagulant, antifungal,
antiinflamatory, anhelmintic, antiplatelet, antiprotozoal and antiviral
substances with actions on the cardiovascular, endocrine, immune and
nervous systems [20]. Nevertheless, marine natural products have been
prominently featured in the area of cancer research [17]. Between 1969
and 1995, 63 marine substances were patented as antitumour agents,
accounting for half the marine molecules patented for pharmaceutical
purposes [21].
6Namely, Australia, Belgium, Bolivia, Brazil, Canada, China, France, Germany,
India, Italy, Japan, The Netherlands, Norway, New Zealand, Philippines, Russia,
Slovenia, Spain, Switzerland, United Kingdom, Uruguay and the United States.
7Echinoderms include starfish, sea cucumbers and sea urchins.
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The focus on cancer stems from three main reasons:
• important funding by the US National Cancer Institute.
• the fact that the cytotoxins that marine invertebrates produce as a
defence from fouling are potential antitumour agents.
• the cancer market is estimated to be US$16 bn annually and
growing.
Consequently, progress in marine cancer research has been
noticeable. In 1951, the arabinosyl-nucleosides of the sponge Tethya
crypta of the Caribbean Sea were discovered. They inspired Ara-C, the
first commercialized antitumour agent of marine origin. Today, more
than 500 substances with potential antitumour activity [22] have been
described; of them, at least 10 highly promising molecules are in pre-
clinical studies, eight in clinical studies and two on the market. Table 2
overleaf summarizes available information on the two commercialized
and eight currently clinically tested marine antitumour agents.
All in all, marine organisms match terrestrial plants, biotechnologies
and synthesis as a source of antitumour agents [22]. Besides, antitumour
agents illustrate the particularities of marine drug development—and,
by extension, marine product development. Therefore, a closer look
at marine bioprospectors, the environmental impact of marine drug
development and industry trends, follows.
3.2. Marine bioprospectors
Marine bioprospectors rely mainly on marine invertebrates as a source
for biologically active molecules. Although the sampling size for
chemical activity scanning has sharply decreased, once an active agent
is identified, large amounts continue to be necessary at least for
establishing its pharmacology and for pre-clinical trials. However,
invertebrates produce these molecules in minuscule quantities: 1 tonne
of Bugula neritrina contains only 0.1–1 g of bryostatin 1 [22]; similarly, it
takes 1 tonne of Ectainascidia turbinata to isolate 1 g of ecteinascidin-743
(ET-743) [23]. Human clinical trials involve the use of further amounts
of active agents: 5 g, in the case of ET-743. Bioprospectors need to
collect large amounts of organisms, obtain them through mariculture, or
chemically synthesize the active agents—all of which involve important
investments. To the uncertainties inherent in drug development from
natural products can be added the high toxicity from active principles,
whose full effects may only show up at the last phases of human trials.
To face the resulting risks, bioprospectors have a double strategy: on
the one hand, they file patents on every aspect of the active agents
they discover; on the other hand, they build strategic alliances with the
pharmaceutical industry.
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Following the tradition in the pharmaceutical industry, marine
bioprospectors file for, and obtain, patents on the active principles
they discover and find a utility for them (see Box 1). These patents
often contain the location where the marine invertebrate was obtained—
sometimes including even latitude and longitude. In the case of
promising substances, bioprospectors do not file a single patent, but
rather a battery of patents, each covering new variations of the same
active agent8, new therapeutic uses, new synthesis steps or processes
or new derivatives. With these patents, marine bioprospectors protect
their research for improving the availability and utility of their active
principles. The higher value of their patent portfolio helps strengthen
their potential for establishing alliances with larger pharmaceutical
companies.
As seen in Table 3 above, the most successful prospectors for
marine antitumour agents identified in the course of this research
are US research centres, both public, like the Universities of Illinois
and Arizona, and private, like the Florida-based Harbour Branch
Oceanographic Institution (HBOI) and the Californian Scripps Institution
of Oceanography (SIO). These institutions’ work is initially funded
by the National Cancer Institution, but they also obtain funds from
licensing their technologies to private companies. These companies
cover the costs of the antitumour agent development—including those
of human clinical trials—in exchange for a privileged position at its
commercialization. Some of these deals have involved pharmaceutical
giants like Novartis (which licensed the HBOI discodermolide) and
Bristol-Myers Squibb (which licensed bryostatin 1). Others involve
specialist companies that bear part of the development costs and link
up with pharmaceutical giants for commercialization. This is the case
with the University of Illinois, which has licensed at least two marine
antitumour agents, ET-743 and aplidin, to the Spanish firm PharmaMar
(see Box 4). In turn, PharmaMar has raised funds from its parent
company, Zeltia, for their development. Finally, after a quite successful
Phase II human trials, in 2001, PharmaMar announced that it had
reached an agreement with Johnson and Johnson to commercialize ET-
743 in the US and Japan. The company expected an income of more than
US$1 bn from this molecule alone [24].
3.3. The environmental impact of marine drug development
In the pharmaceutical industry, the ideal marine active agent can be
synthesized in the laboratory immediately after its structure has been
elucidated. Industry would only have to care about the environmental
8For example, the Arizona State University holds US Patent 4,560,774 covering
bryostatins 1 to 3, and US Patent 4,611,066, covering bryostatins 4 to 8.
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Table 3
Bioprospecting institutions identified in the course of this research, some of the
marine active agents they have patented and the number of patents they hold
Group Marine active agents Number of US
patents
Comment
Cancer Research
Institute of the
Arizona State
University
Bryostatins,
dolastatins,neristatins,
dyctiostatin, and
cephalostatins
23 Public sector
Harbor Branch
Oceanographic
Institution
(Florida)
Cyclohexadienones,
discodermolides,
indole alkaloids,
misakinolides, cyclic
peroxides,
discorhabdins,
antitumour alkaloids,
cyclohexadienones
60 Private founda-
tion
with strong
links
to public
universities
PharmaMar Crambescidins,
kalahide F,
sesbanimide, MT 332,
epidioxymanadic
acids A and B,
mycaperoxides (the
company claims it has
patent applications on
28 innovations)
6 (the company
claims 222)
A subsidiary of
Zeltia, a Spanish
chemical group.
University of
Illinois
Ecteinascidins,
didemnins,
spisulosins
7 Public sector
impact of its sampling activities for chemical screening and of that of
the harvesting of the specimens necessary to isolate and characterize the
active principle. Industry would then be able to obtain the increasing
amounts of active agent necessary to undertake pre-clinical studies,
human clinical trials and, eventually, commercialization, free of any tie
to the oceans. Industry also prefers synthesis because it can then obtain
derivatives with improved action or fewer negative side effects.
However, most marine active agents are highly complex and prove
very difficult—and expensive—to synthesize. In the meantime, pre-
clinical and human clinical studies rely on marine invertebrates. Some
companies continue to depend on wild populations to feed their studies.
Others have invested in cultivating marine invertebrates as a way to
ensure and increase their supply. On the whole, the environmental
impact of the development of marine drugs differs with the biology
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of the exploited species and the concentration and complexity of their
active agents.
As already seen, the direct environmental impact of the collection
of marine species for chemical screening is now much lower than it
was 30 years ago. The higher efficiency and speed of current screening
technologies may, in turn, help quicker identify more potentially
interesting species. The environmental impact of aggressive scanning
may simply be replaced by that of the exploitation of more species.
When the concentration of the active principles is very low, even
initial collection efforts may prove unsustainable. An example is
dolastatin 10, which was isolated in very low yield (0.1–1 g per tone)
from the sea hare Dolabella auricularia from the Indian Ocean. Such
large (1,600 kg) collections were made that the project was criticized
as an assault on biodiversity conservation [17]. Dolastatin 10 was
subsequently synthesized and the molecule followed its way through
the clinical evaluation process.
The sea squirt, Ecteinascidia turbinata, delivers its active agent, ET-
743, at the same concentrations as D. auricularia. However, E. turbinata
is a fast-growing species, and, in principle, it is possible to obtain three
crops a year from the mangrove swamps of the Caribbean. This is only
possible, though, if collectors are careful and the mangrove roots the
species colonizes are left untouched—which is not always the case [23].
ET-743 is also an example of the possibilities of invertebrate
mariculture. Using a technology developed by CalBioMarine
Technologies, PharmaMar has cultivated it in the Atlantic Ocean and the
Mediterranean Sea. PharmaMar claims that, in the year 2000, it obtained
96 tonnes of Ecteinascidia turbinata from its aquaculture and mariculture
facilities. CalBioMarine Technologies has also successfully cultivated
Bugula neritina, the bryozoan producing bryostatin 1 [22].
However, mariculture is not an ideal solution, either for the
environment, or for the pharmaceutical industry. An environmental
impact assessment of the introduction of these aquaculture activities
should be conducted, especially when the species is to be cultivated
outside its natural distribution range or living conditions. In addition,
successful mariculture does not necessarily put an end to the harvesting
of natural ecosystem—-at least, PharmaMar has not abandoned the
collection of E. turbinatain form the Caribbean Sea [25].
For industry, mariculture is only a mid-term solution for the problem
of supply of active agent: it can help through the drug development
process, but it cannot produce the amounts of active agent required for
large-scale commercialization. In order to feed the estimated market of
2.5 kg of ET-743 a year, PharmaMar would need to grow 2,500 tonnes of
E. turbinata! Therefore, in parallel to its mariculture projects, the Spanish
firm has developed a synthesis process for ET-743 [18]. In fact, some
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experts think that reliance on mariculture is the main reason behind
Bristol-Myers Squibb dropping its exclusive licence on bryostatin 1 [22].
3.4. Coastal communities and marine bioprospecting
To find new active agents, marine bioprospectors prefer screening
marine organisms, rather than coastal communities’ knowledge. In
turn, bioprospectors regard highly local knowledge of biodiversity
distribution; indeed, their safety relies on local fishermen’s knowledge
of tides and ability to avoid danger [26].
Bioprospectors rely on professional scuba divers, rather than local
fishing communities for harvesting invertebrates. The National Cancer
Institute has used the Coral Reef Research Foundation for many
years. The main reason for this is that samples are taken according
to established protocols and have to be frozen immediately. Fishing
communities can only harvest these resources after extensive training,
but few—if any—programmes for such training have been implemented
[26].
In contrast, industrial fishing boats are in a much better position
to collect interesting invertebrates—at the cost of a far greater
environmental impact.
When the shift towards mariculture production and chemical
synthesis of marine active agents are seen in the light of these limitations,
the scope for coastal communities’ direct participation in sustainable
fisheries of active agent-producing organisms seems quite limited. The
first real test of large-scale harvesting of a marine invertebrate has come
from the commercialization, by the cosmetics firm Este´e Lauder, of a
partially purified extract of Pseudopterogorgia elisabethae, a gorgonian
from the Caribbean Sea. This extract contains pseudopterosins, which
are antiinflammatory agents. According to John Faulkner of the Scripps
Institution of Oceanography of the University of California, more than
4.5 tonnes of gorgonians had been extracted by the year 2000. The
gorgonians, which occur between 13 and 23 m depth, are pruned by
hand along an approximately 96-km length of the Bahamas coastline.
Diving is limited to about 18 m, so that the deep-water specimens
provide a reservoir of breeding stock. Re-growth occurs in about one-
and-a-half years. Researchers believe that the harvesting of P. elisabethae
populations can be sustainable, if managed carefully.
3.5. Trends for the future
Industry experience in marine antitumour agent development shows
that (i) the oceans are a valuable source of antitumour agents; (ii)
these agents hold pharmacological properties and action mechanisms
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similar to usual antitumour substances; and (iii) the main obstacle
to their development is the difficulty in obtaining the products in
enough quantities for the industrial production of the future drug [22].
Analysts hope that two emerging trends may help overcome these
barriers. First, synthetic methods are constantly improving so that even
complex molecules or, preferably, simpler analogues based on marine
metabolites, can be synthesized on industrially useful scales. Second,
there is a growing body of evidence to indicate that many of the active
agents present in invertebrates, in reality, come from their diet or from
bacterial symbionts or epybionts.
If the latter were the case, it would be possible, in principle, to obtain
the active agents from the in vitro culture of either the invertebrates’
cells and their bacterial symbionts, or the epybionts. To date, efforts
to cultivate sponges’ cells have failed as they become inactive after
a certain number of divisions [23]. Marine bacteria are even more
difficult to grow. Ultimately, the hopes of marine bioprospectors lie in
current molecular genetics techniques. These could allow identification
of the bacterial genes involved in the metabolic pathway producing
the active agents. Then, in theory, it would possible to transfer the
genes involved in this metabolic pathway to familiar bacteria such as
Escherichia coli, which is already used industrially to produce, among
other things, human insulin. Already, advances in marine biotechnology
have resulted in an increase in the number of papers reporting studies
on microorganisms’ marine natural products. Marine drug production
may be slowly shifting from the oceans to the tubes; in the process, the
prospects of coastal communities participating in sustainable fisheries of
active agent-producing organisms are fading.
4. Aquaculture
Between 1987 and 1997, the global production of farmed fish, shellfish
and crustaceans (collectively called ‘fish’) more than doubled in weight
and value, as did their contribution to world fish supplies [9].9
Aquaculture embraces a range of practices with different histories and
implications for aquatic biodiversity. In low-external input aquaculture
(also called extensive aquaculture), raised animals are protected from
predators and competitors; in semi-intensive aquaculture, their food
supply is enhanced; in intensive aquaculture, the farmer provides them
all their nutritional requirements, which allows generating high fish
densities. Aquaculture uses more than 220 species of fish. Table 4
compiles the world’s aquaculture production in 1998.
9Much of the general information on aquaculture in this report is extracted from the
excellent article by Nalylor et al.
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The raising of carp within complex agricultural rice systems in
China is perhaps as old as rice culture itself; rice farmers in Kerala,
India, have, for centuries, managed a polyculture system based on
rotational cultivation of rice and shrimp, called chemmeenkettu; the
Japanese learned to favour the growing of seaweed for their diet
300 years ago. The fruit of farmers’ ingenuity and inventiveness in
biodiversity management, such low-external input aquacultural systems
do not compete with other uses of the aquatic environment, but rather
complement them by helping to close nutrient cycles [27].
Some sources report, unfortunately, that in China and other parts of
Asia, many small-scale farming operations are intensifying as land and
water resources become increasingly scarce and valuable [9]. In contrast
with extensive systems, intensive aquacultural systems have a much
shorter history: they, are in fact, the result of the “Blue Revolution”,
that is, the reproduction of the “Green Revolution” production model
in aquaculture.
Consequently, and just like their terrestrial counterparts, intensive
systems require the use and management of inputs, generate large
amounts of waste products and are more susceptible to the spread of
pathogens.
The Blue Revolution incorporated new, high-value and often
carnivorous species into aquaculture, like crustaceans, salmon and
marine fish. Nevertheless, it has also targeted extensive aquacultural
systems, mainly through the introduction of improved tilapia—the first
case of targeted efforts to genetically improve an aquacultured species.
As seen in Table 4 overleaf, the bulk of aquacultural production
is made up by freshwater fish, molluscs and aquatic plants [31]—
producedmainly under extensive conditions. In terms of value, themost
important farmed groups are freshwater fish, crustaceans and molluscs.
In general, the Blue Revolution carnivorous species fetch the highest
prices. Of course, production costs for intensive aquaculture are higher
too—feed accounts for half of them.
Chinese farmers probably started to domesticate carp thousands of
years ago, as they domesticated rice. The domestication of carp is the
exception rather than the norm in aquaculture, which has relied on
fish stocks from a narrow centre of origin, with subsequent inbreeding
causing impaired genetic performance. Tilapia is a good illustration.
According to Roger Pullin, a former staff of the International Centre
for Aquatic Living Resources Management (ICLARM), in 1962, some
tilapia specimens were collected from the open waters in Egypt and
shipped to Japan. In 1965, some of their descendants were shipped to
Thailand and they produced a strain that has since then been widely
farmed. A few fish of this strain were introduced in the Philippines in
1972 and their descendants have since been farmed there [29].
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Table 4
Total aquacultural production in 1998
Species group Total Total Average Main farming
Species production value price farming
group Mt MUS$ 1000US$/t method
Freshwater fish 17355 19737 1.137 Extensive and intensifying
Molluscs 9143 8479 0.927 Extensive
Aquatic plants 8568 5377 0.628 Extensive
Diadromus fish 1909 5907 3.094 Intensive
Crustaceans 1564 9234 5.904 Intensive
Marine fish 781 3396 4.348 Intensive
Other aquatic animals 111 330 2.973 Several
Source: FAO State of the world fisheries and aquaculture 2000
Despite Filipino farmers’ selection efforts, in 1989, their tilapia
aquaculture turned out to be less efficient than new founder stocks
collected from the wild in Egypt. To solve this problem, ICLARM
launched the Genetic Improvement of Farm Tilapia (GIFT) project to
develop genetic resources for tilapia, which resulted in the creation of
the “super-tilapia” using wild populations from Egypt, Senegal, Ghana
and Kenya [30].
Although modern breeding in aquaculture is a recent phenomenon
and the majority of farm-raised aquatic animals and plants are very
similar to their wild forms, selective breeding programmes have
already yielded significant and consistent gains of 5–20 per cent per
generation in species of, inter alia, Atlantic salmon, catfish and tilapia
[31]. In fact, the optimistic prospects for the future contribution of
aquaculture to the world’s food security rely on productivity increases
resulting from selective breeding. Accordingly, interest in selective
breeding programmes is increasing worldwide: in Asia and Africa,
they are envisaged for shrimp, tilapia, common carp and rohu; in the
Mediterranean region, their application to marine fishes such as sea
bass and sea bream has been identified as a top priority [32]. Like the
GIFT project, the success of these and other programmes will depend
on their capacity to access those cultivated species’ genetic diversity
in the wild (in farmers’ ponds, in the case of carp). However, such
access is problematic as aquatic biodiversity, especially in freshwaters,
is threatened by human activities, further eroded by aquaculture itself.
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4.1. The dwindling base for aquaculture
Marine fish genetic diversity is still not well understood, and there is
no agreement on the main factors that contribute to it. In contrast,
it is commonly accepted that freshwater fish populations, which have
been isolated from others for long periods of time, have adapted to their
environments through particular genetic combinations. Freshwater fish
diversity is embodied in those particular genetic combinations.
Fish genetic diversity is eroded, among other factors, by fishing—
including the fishing down of the aquatic web—habitat destruction,
pollution, the introduction of alien species and restocking with alien
populations. Human ability to alter freshwater environments—through
dam construction, water transfers between different hydrographical
basins, the modification of rivers’ paths, etc—is the most serious threat.
At the species level, freshwater fish are the most threatened of all species
groups that are widely exploited by humans. Erosion is impressive:
more than 300 stocks of native Pacific salmonids are at risk of extinction
in the Pacific northwest and even the US does not have enough resources
to conserve them all [33]; the introduction of the Nile Perch in Lake
Victoria led to the loss of 200–300 fish species. Unfortunately, the list
could go on and on.
Aquacultural activities have also contributed to the erosion of fish
genetic diversity, at many different levels:
• Since it is impossible to avoid the escape of aquacultured species
into the environment, aquaculture has an impact on biodiversity,
when it involves the introduction of aliens into an ecosystem.
Tilapia is a case in point. Introduced in more than 85 countries,
the species is highly carnivorous and can expand at the expense of
less aggressive indigenous fish. In fact, it has already led to the
depletion of a fish indigenous to Costa Rica, the guapeta [34].
• The large-scale escape of cultured populations into freshwater
environments may lead to the introgession of the cultivated
germplasm into the genetic structure of the wild populations. In
the Magagudavic River, Canada, 1995 estimates indicated that 90
per cent of the salmon caught was of farmed origin.
• Newly introduced populations have sometimes brought parasites
or viruses with them that have, in turn, affected wild biodiversity
[9]. Many native populations of Atlantic salmon in Norway are
threatened with extinction from a parasite introduced through
genetically resistant salmon populations from the Baltic Sea. More
recently, the white spot virus that caused catastrophic losses in
shrimp farms across Asia has brought high mortalities into Texas
shrimp farms and may cause mortality of wild crustaceans [9].
• Fishing for seed to stock aquacultural operations may have large
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consequences for wild fisheries. An example is the farming of
milkfish in the Philippines. Milkfish constitute only 15 per cent of
total finfish fry collected inshore by seine nets—the remaining 85
per cent are discarded and left to die on the beach. In India and
Bangladesh, up to 160 fish and shrimp fry are discarded for every
fry of the giant tiger shrimp collected to stock ship ponds [9].
• Aquaculture also has a direct impact on fish diversity because
it contaminates the water and involves habitat destruction—
especially shrimp ponds in mangrove areas—and, more indirectly,
because it promotes the use of low-value fish species as feed, as
exemplified by Thai trash fisheries.
4.2. Poor knowledge
Although the number of farmed species reported to the Food and
Agriculture Organization of the United Nations (FAO) is increasing,
there is a vast amount on information on genetically differentiated
strains, races and varieties that is not well-reported, hampering both
conservation efforts and selective breeding programmes.
4.3. Initiatives
The realization of the erosion of fish genetic diversity has resulted in
efforts to reverse these trends and promote the in situ conservation
of fish aquatic diversity through a variety of initiatives, projects,
regulations and policies on coastal areas development, alien species
introduction, re-stocking, genetic conservation and quarantine periods.
Unfortunately these regulations and policies are not always adequate
and/or enforced, particularly—but by no means only—in developing
countries [35]. Meanwhile, industry, the public sector and indigenous
peoples have launched programmes for the ex situ conservation of
fish genetic resources, by building gene banks of cryopreserved fish
sperm. Such gene banks can then be used to preserve diversity and as
broodstock for breeding programmes.
The World Fisheries Trust (WFT), a Canadian non-for-profit
organization, has assisted the Shuswap First Nation of Canada in
preserving the dwindling genetic variability in several species and
stocks of Pacific salmon in their territory in southwestern British
Columbia. In Brazil, the WFT is involved in a gene banking programme
that aims to collect and use genetic material from indigenous migratory
species. Brazilian fish farmers are shifting from the culture of alien
species (like Chinese carp and tilapia) to these migratory species, which
command a much higher price. For many of these species, wild
broodstock are becoming harder and harder to find [36].
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After the success of the GIFT project, in 1993 ICLARM set up
the International Network on Genetics in Aquaculture (INGA), which
supports its member countries through strengthening their research
capacities, supporting their national breeding projects, and promoting
germplasm exchange. Currently, 13 Asian and African countries have
joined this initiative [37]. FishBase (http://www.fishbase.org) is
another ICLARM tool to document available information on fish genetic
diversity and its use in aquaculture.
The expectations on long-term productivity increases derived from
the use of fish genetic resources have also resulted in the extension
of property rights over them—in a process that parallels that of plant
genetic resources for agriculture. As a member of the Consultative
Group on International Agricultural Research (CGIAR), ICLARM has
endorsed the CGIAR’s IPR policy. The CGIAR is promoting the transfer of
intensified production systems for the benefit of the poor. Its IPR policy
is highly controversial. On the one hand, it is designed to prevent others
from obtaining IPRs on genetic resources as collected and provided by
gene banks. On the other hand, it allows for the “defensive patenting”
of inhouse developed technologies and products. No matter whether
this “defensive patenting” intends to ensure that the CGIAR inventions
will not be slightly modified and patented by somebody else, or seeks
providing the group with bargaining chips to negotiate the transfer
of technologies from the private sector, it legitimates the patenting of
genetic resources.
The trend towards the patenting of fish genetic resources, and even
the patenting of new breeds of fish, is accelerating as the aquaculture
industry applies biotechnology shortcuts—including hybridization, sex
manipulation, polyploidy and genetic engineering—which are more
amenable to patenting than selective breeding.
5. Other Industries
The pharmaceutical and aquacultural industries are not the only
prospectors of marine biodiversity. Although a detailed description
of these other branches is beyond the scope of this report, a brief
introduction to some of them, organized as per the marine ecosystems
they exploit, follows.
Phytoplankton is grown industrially to produce raw biomass
and value-added food and feed supplements, such as proteins,
eicosapentaenoic acid and betacarotene (respectively obtained from
Spirulina, Nannochloropsis and Dunaliella). In some developing countries,
the expansion of shrimp farming has led to microalgae cultivation to
feed larvae. Phytoplankton is also used for environmental cleansing.
Besides its current uses, phytoplankton holds a large potential source
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of genes and substances, which is already attracting the pharmaceutical
industry. In 1998, the Department of Biotechnology of the Tokyo
University of Agriculture and Technology claimed that the lines in
its phytoplankton collection could produce a range of substances—
from plant growth regulators (of potential interest to the agrogenetic
industry) to new antiviral and antibiotic molecules (attractive to the
pharmaceutical industry) to ultraviolet filters, which might feed the
cosmetic and personal care industry. According to the Department’s
Tadashi Matsunaga, most of the samples of this collection were isolated
in the coasts of several regions in Asia and Micronesia [38]. As already
mentioned, phytoplankton is now also attracting the pharmaceutical
industry.
The microorganisms living in deep-sea vents, the bacteria digesting
whale skeletons in the bed of the Arctic Ocean and the bacteria looming
in highly saline lagoons share the ability to survive in conditions
that, for most of the rest of organisms we know, and certainly for
human beings, are extreme conditions. Consequently, they are referred
to as “extremophiles”. A branch of the biotechnology industry is
specialized in identifying extremophile microorganisms, cloning their
genetic material and producing its enzymes10 in laboratory bacteria.
These enzymes can be then used in industrial processes at high
temperatures or under high pressures—depending on the organism they
come from. They can also be genetically modified to fit a particular
process even better. Some companies working to develop extreme
enzymes out of extremophiles are Diversa, Novo Nordisk, Genencor,
Amgem and Recombinant BioCatalysis.
As a last example, another important research line is looking
for antifouling molecules in the same sessile invertebrates where the
pharmaceutical industry is looking for antitumour agents. Non-
pollutant antifouling molecules of marine origin could save annual
losses of more than US$1.5 bn [39].
6. The International Legal Frame of Control over
Marine Biodiversity
The international community deals with control over marine biodiver-
sity mainly through three Conventions that have become international
law: The United Nations Convention on the Law of the Sea (UNCLOS),
the Convention on Biological Diversity (CBD) and the Trade-Related As-
pects of Intellectual Property Rights (TRIPS) Agreement of the World
Trade Organization (WTO).
10An enzyme is a protein that catalyzes chemical reactions within an organism’s
metabolism.
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6.1. The United Nations Convention on the Law of the Sea
(UNCLOS)
Negotiated between 1973 and 1982 and entered into force in November
1994, UNCLOS is the international convention governing the world’s
oceans. UNCLOS is relevant to control over biodiversity in three ways:
• it establishes the rights and obligations of coastal States on the
marine areas surrounding them, and the rights and obligations of
other States on those waters;
• it sets the conditions to conduct marine research; and
• it forces countries to give access to “surpluses”.
UNCLOS grants coastal States full sovereignty over their territorial
sea—a belt of sea adjacent to the countries’ coast, no wider than 12
nautical miles (UNCLOS Art.2). UNCLOS also establishes the Exclusive
Economic Zone (EEZ), a belt of sea adjacent to the countries’ coast, no
wider than 200 nautical miles, where the coastal State has “sovereign
rights for the purpose of exploring and exploiting, conserving and
managing the natural resources, whether living or non-living”(UNCLOS
Art. 56). Beyond countries’ EEZs are the high seas, to which all countries
have free access rights. Therefore, UNCLOS both grants and limits the
extension of coastal countries’ rights into the seas and their inhabitants.
The CBD would later extend sovereignty to cover the biodiversity—and
the genetic resources—in territorial seas and EEZs.
UNCLOS sets some obligations on scientific marine research. It
grants coastal States the exclusive right to regulate, authorize and
conduct marine scientific research in their territorial sea—just as they
have in their land territories (UNCLOS Art.245). In the EEZs, these
rights are modulated by the obligation, in normal circumstances, to
grant foreigners consent for marine scientific research (UNCLOS Art.246).
These foreigners are subject to a number of obligations, including
providing information on their research activities, accepting the coastal
State’s participation in research programmes, and providing access for
the coastal State to all data and samples derived from the marine
scientific research project (UNCLOS Art.249). Such provisions oblige
any company wishing to carry on bioprospecting agreements to inform
coastal countries of its purpose to do so. This is a first—and strong—step
towards the concept of “previous informed consent” developed under
the CBD.
UNCLOS obliges coastal States to determine their capacity to harvest
the living resources of the EEZ and give other States access to the surplus
of the allowable catch (UNCLOS Art.62).
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6.2. Convention on Biological Diversity (CBD)
The Convention on Biological Diversity (CBD or the Convention) was
born out of a bundle of common concerns and conflicting interests,
including:
• the growing recognition that biological diversity is a global asset of
tremendous value to present and future generations;
• the unprecedented threats to species and ecosystems;
• the rise of biotechnology, genetic engineering in particular, as the
new area of industrial growth for the North;
• the spectacular increase of IPR claims on developed countries’ “in-
ventions” building on genetic resources and associated knowledge
from developing countries;
• increasing pressures on developing countries to have them accept
such IPRs; and
• the then existing regime of free access to biodiversity “as found in
nature”, which prevented developing countries from:
? protecting their peoples from the appropriation of their
biodiversity and associated knowledge
? avoiding the privatization of this diversity by denying access
to it; and
? participating in the benefits arising out of the use of the
biodiversity hosted in their territories.
The CBD is a compromise on these common concerns and conflicting
interests, achieved by an Intergovernmental Negotiating Committee,
and adopted on 22May 1991 in Nairobi. The Conventionwas opened for
signature at the 1992 United Nations Conference on Environment and
Development (UNCED) in Rio de Janeiro. The CBD came into force and
became international law on 29 December 1993, after it had been ratified
by 30 countries. By March 2002, it had been signed by 168 countries and
ratified by 154.
The Convention (see Box 2) is a framework agreement that gives
goals and policies. The Conference of the Parties (COP) is responsible
of further implementing the CBD through its meetings, special meetings
on specific issues, and the promotion of protocols.
The compromise attained by the CBD is very well summarized by its
objectives, which are contained in Article 1:
“The objectives of this Convention, to be pursued in accordance with
its relevant provisions, are the conservation of biological diversity, the
sustainable use of its components and the fair and equitable sharing of
the benefits arising out of the utilization of genetic resources, including
by appropriate access to genetic resources and by appropriate transfer of
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relevant technologies, taking into account all rights over those resources
and to technologies, and by appropriate funding.” (CBD, Article 1)
The CBD acknowledges three types of rights over genetic resources
and technologies. For the first time, the CBD establishes that States
have sovereign rights over their biodiversity and the genetic resources
it contains (CBD Art.3). Simultaneously, the Convention acknowledges
IPRs on the technologies and products derived from the (industrial) use
of those genetic resources (CBD Art.16).
Therefore, the States that are parties to the CBD must abide by
national sovereignty and IPRs. The CBD also acknowledges the rights
of “indigenous and local communities relevant for the conservation and
sustainable use of biological diversity”(CBD Art. 8(j)).
However, the rights of these “indigenous and local communities”
are not explicitly recognized in the text of the CBD; furthermore, their
enforcement is subordinated to national legislation. Consequently,
parties are not obliged to acknowledge such rights to any meaningful
extent—unless the Convention develops a Protocol or an agreed
interpretation of the Parties’ obligations on this regard.
The Convention is based on an intimate link between biodiversity
conservation and sustainable use. Although the term ‘sustainable
use’ is open to many interpretations, its use in the Convention is
biased towards industrial use and biotechnology. This is so because
developing countries’ claim for compensation for industry’s profits
upon their genetic resources, as well as developed countries’ interest
to ensure access to those genetic resources, underpin the Convention.
The potential cash flows and technology transfers resulting from the
development of a market on developing countries’ genetic resources
have since dominated the CBD agenda. As a result, as CBD provisions
are being developed for implementation, countries are urged to
make transparent, reliable and simple access mechanisms, which are
convenient for bioprospectors. Countries are also urged to involve their
indigenous and local communities in national access legislations. To
facilitate this involvement, countries are encouraged to provide their
indigenous and local communities with training on the negotiating of
agreements and taxonomy.11
What is even worse, the rights of indigenous and local communities
are being assimilated to IPRs. The CBDwas born as an effort to pay justice
to indigenous peoples and local communities suffering from unbridled
biopiracy.
11See, for example, the recommendations adopted by the Ad Hoc Open-Ended
Working Group On Access and Benefit-Sharing (UNEP/CBD/COP/6/31 October 2001).
In spite of Article 10(c), TEKS are perceived more as bargaining opportunities to
establish access and benefit sharing agreements with industry than as objects of
conservation and development of their own.
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Box 2
The CBD in a nut-shell
The first operative provisions of the CBD (Art 6 to 14) cover the
obligations of the States that are parties to the Convention (parties) to
establish the foundations for the conservation and sustainable development
of their biodiversity. Such obligations include developing national strategies
for the conservation and sustainable use of biodiversity; identifying,
monitoring and establishing databases on the key components of their
biodiversity; implementing in situ conservation mechanisms; implementing
supportive ex situ conservation mechanisms, preferably in the countries
of origin; promoting the sustainable use of biodiversity—including its
customary use; incentivizing biodiversity conservation and sustainable
use; encouraging research and training; promoting public education
and awareness, and conducting environmental impact assessments; and
minimizing adverse impacts of its projects, programmes and policies.
The rights of indigenous and local communities are implicit in this first
part of the Convention, in the provisions of Article 8(j), which reads as
follows:
Art 8. In situ conservation
Each Contracting Party shall, as far as possible and as
appropriate:
(j) Subject to its national legislation, respect, preserve and
maintain knowledge, innovations and practices of indigenous
and local communities embodying traditional lifestyles relevant
for the conservation and sustainable use of biological diversity
and promote their wider application with the approval and
involvement of the holders of such knowledge, innovations and
practices and encourage the equitable sharing of the benefits
arising from the utilization of such knowledge, innovations and
practices.
Furthermore, Article 10(c) requires parties to “protect and encourage
customary use of biological resources in accordance with traditional
cultural practices that are compatible with conservation or sustainable use
requirements”.
The obligations under these first operative provisions should result in
a real improvement of the conservation and sustainable use of biodiversity,
the first two objectives of the Convention. They provide the basis to attain
the rest of the CBD objectives, promoting access to genetic resources and
technologies, which are addressed in the provisions under Articles 15 to 19.
(contd. . . )
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Box 2: The CBD in a nutshell (. . . contd )
Countries are obliged to establish mechanisms to grant access to their
genetic resources and biodiversity. This access is conditioned to the Prior
Informed Consent (PIC) from the country providing the genetic resources,
and it is subject to the fair and equitable sharing of the benefits. The
conditions for access and benefit sharing (ABS) are established in a contract
between industry and the State—Art. 8(j) only recommends the participation
of “indigenous and local communities” in such contracts, which is subject to
national legislation.
The provisions on access to genetic resources are complemented by
others on the transfer of the technologies developed. Such technology
transfer is to acknowledge IPRs on these technologies; in this sense, the
CBD text promotes, rather than prevents, the adoption of IPR systems on
biodiversity. However, the Convention includes a provision requesting
countries to co-operate to ensure that IPRs are “supportive of and do not
run counter to [the CBD] objectives” (CBD Art.16.5). This attempt at ensuring
that the CBD takes preference over private IPRs upset the United States of
America so much that it became one of the reasons why it never ratified the
Convention [40].
The Convention also requests countries to exchange information on
biodiversity conservation and sustainable use from all publicly available
sources, including information on indigenous and local communities,
and to undertake technical and scientific co-operation—through which
developed countries support developing countries’ capacities. In particular,
the Convention encourages “the effective participation in biotechnological
research activities” by countries providing genetic resources, and stresses the
need to share the benefits arising from biotechnologies with those countries,
taking into account the adverse effects that living modified organisms
resulting from biotechnology may have on biodiversity.
The last part of the CBD text (Articles 33 to 42) contains the CBD
functioning provisions, including the establishment of a fundingmechanism,
under the guidance of the COP, to help developing countries meet the
full incremental costs to them of implementing measures which fulfill
the obligations of the CBD; the relationship with other international
conventions—including consistency with UNCLOS; the COP; the Secretariat;
the Subsidiary Body on Scientific, Technical and Technological Advice, made
up of competent national representatives; reports; dispute settlement, and
the means for the modification of, and adhesion to, the Convention.
Many indigenous peoples, local communities and groups supporting
them hope that Article 8(j) will allow the definition of a clear set of
indigenous peoples’ and local communities’ rights, based on their own
needs. Such rights would empower indigenous peoples and local
communities to ensure the conservation and sustainable development
of their TEKS.
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They would also allow these peoples and communities to
participate in the benefits arising from the sharing of their knowledge.
Unfortunately, currently the CBD is even taking as a reference the work
that the World Intellectual Property Organization (WIPO) is developing
to incorporate TEKS into the IPR umbrella, in order to accommodate the
CBD to the TRIPS setup (see later)12. This, in spite of WIPO’s mandate to
promote the IPR systems that allowed biopiracy in the first place.
If these trends are left unchecked, indigenous and local communities
may find, at the end, that the only gain they have accrued from the CBD
is a small fraction of the benefits that others are gaining from using their
biodiversity (as illustrated in Table 5 overleaf); a far cry from control
over their resources, knowledge systems and livelihoods that could
emerge from the conservation and sustainable development of cultural
biodiversity and the TEKS it feeds.
6.3. Trade-RelatedAspects of Intellectual Property Rights(TRIPS)
The Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agree-
ment of the World Trade Organization (WTO) came into force on 1 Jan-
uary 1995, as an outcome of the negotiations of the Uruguay Round of
the General Agreement of Trade and Tariffs (GATT).13
Some of the main features of TRIPS follow:
• Setting minimum standards.
TRIPS forces countries that are members of the WTO to fulfill
minimum standards for protection in the areas of copyright,
trademarks, geographical indications, industrial designs, patents,
layout designs of integrated circuits and undisclosed information.
• Equal treatment for all inventors and all exporters.
The National Treatment clause requires WTO members to treat the
nationals of all other member countries exactly the way that they
treat their own nationals; the Most-Favoured-Nation (MFN) clause
requires them to treat the exporters of all other member countries
12See Recommendation 2/6 on the assessment of the effectiveness of existing
subnational, national and international instruments, particularly intellectual property
rights instruments, that may have implications for the protection of the knowledge,
innovations and practices of indigenous and local communities, in the Report of
the Ad Hoc Open-Ended Inter-Sessional Working Group on Article 8(j) and Related
Provisions of the Convention on Biological Diversity on theWork of Its SecondMeeting
(UNEP/CBD/COP/6/7).
13This analysis feeds in part on the assessment of the TRIPSAgreement by the Genetic
Resources Action International GRAIN in The International Context of the Sui Generis
Rights Debate in Signposts to Sui Generis Rights: resource materials from the international
seminar on sui generis rights co-organized by the Thai Network on Community Rights
and Biodiversity (BIOTHAI) and GRAIN, Bangkok, 1-6 December 1997, pp. 9–27.
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exactly the same as they treat those of their most favoured trading
partner.
• Transition periods.
Developed countries were to implement TRIPS within one year after
the Agreement was adopted; developing countries had a 5-year
transition period—until 1 January 2000; lastly, the transition period
of least developed countries (LDC) was established as 10 years—
until 1 January 2005.
• Dispute settlement and retaliation.
Countries failing to fulfill TRIPS requirements may be challenged
before a WTO dispute settlement mechanism and eventually be
subject to retaliatory measures in any segment of their trade.
• Patenting obligations.
Under TRIPS Article 27 (see Box 3), countries are obliged to grant
patents for any product or technology, in all fields of technologies.
The only exceptions are:
. inventionswhose utilization is against ordre public andmorality.
. diagnostic, therapeutic and surgical methods.
. plants and animals other than microorganisms, although States
must grant protection over plant varieties through an effective
sui generis system.
The inclusion of IPRs in the Uruguay Round negotiations was
the direct result of industry pressure over developed countries’
governments through their key trade organizations: the International
Property Committee (IPC) of the US, the Japanese Federation of
Economic Organizations, and the Union of Industrial Employees
Confederations of Europe [41]. Industry claimed that the absence of
strong IPRs in developing countries was a barrier to trade, costing some
US$200 bn per annum in lost royalties [42]. In fact, the industrialized
world holds 97 per cent of all patents, most of which are in the hands of
large corporations, and residents of industrial countries hold over 80 per
cent of patents granted in developing countries [43].
Furthermore, TRIPS was expressly designed to ensure that IPRs
could be universally applied to all technologies, especially those that
had previously been declared unsuitable for monopoly rights at the
national level—which include pharmaceutical products, food and living
beings [42] (see Box 1). For comparison, Spain has granted patents on
pharmaceutical molecules only since 1992.
The exceptions to patentability specified in Article 27 are those
existing in the European Patent Convention (EPC), to which most EU
Member States and other European countries were parties to when
TRIPS was negotiated. Developing countries took advantage of the
EU’s unwillingness to accept patents over plant varieties and animals.
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Box 3
TRIPS Article 27: Patentable Subject Matter
1. Subject to the provisions of Paragraphs 2 and 3, patents shall be available
for any inventions, whether products or processes, in all fields of
technology, provided that they are new, involve an inventive step and
are capable of industrial application. Subject to Paragraph 4 of Article
65, Paragraph 8 of Article 70 and Paragraph 3 of this Article, patents
shall be available and patent rights enjoyable without discrimination as
to the place of invention, the field of technology and whether products
are imported or locally produced.
2. Members may exclude from patentability inventions, the prevention
within their territory of the commercial exploitation of which is
necessary to protect ordre public or morality, including to protect human,
animal or plant life or health or to avoid serious prejudice to the
environment, provided that such exclusion is not made merely because
the exploitation is prohibited by their law.
3. Members may also exclude from patentability: (a) diagnostic,
therapeutic and surgical methods for the treatment of humans or
animals; and (b) plants and animals other than micro-organisms, and
essentially biological processes for the production of plants or animals
other than non-biological and microbiological processes.
However, Members shall provide for the protection of plant varieties either
by patents or by an effective sui generis system or by any combination thereof.
The provisions of this subparagraph shall be reviewed four years after the
date of entry into force of the WTO Agreement.
The exclusion of plants, animals and essentially biological processes
was to be reviewed four years after the entry into force of TRIPS—one
year before developing countries’ deadline to implement TRIPS, and
six before least developed countries’ deadline. Launched in 1999, this
review is still open.
Article 27.3(b), and the possibility to review it, elicited intense debate
about WTO members’ obligation to “provide for the protection of plant
varieties either by patents or by an effective sui generis system or by
any combination thereof.” The position of developed countries was
to strengthen the privileges for industry. For the EU, Japan and the
US, this provision indicated the need for all countries to adopt Plant
Breeders’ Rights (PBR), a special form of IPR covering plant varieties,
according to the standards of the International Union for the Protection
of Plant Varieties (UPOV). The UPOV system is based in uniformity,
distinctiveness and stability and is designed for industrial agriculture.
It was clear that the US intended to either include UPOV as the tool to
protect plant varieties, or get rid of Article 27.3(b) and its restrictions
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to the patenting of life forms altogether. The EU arrived at this review
with its homework done. It had approved its most contested piece
of legislation, the Directive of the Parliament and the Council on the
Legal Protection of Biotechnological Inventions (the European Patent
Directive, or EPD), whichmade the patenting of animals, plants and their
parts and genes (including human parts and genes) possible. Therefore,
the EU was ready to follow the US.
In contrast, NGOs concerned with small farmers and food security
and developing countries took a very different approach to the review,
which was articulated in many different positions. Some of them
considered that the sui generis provision allowed for the development of
systems effective to protect farmers’ rights to save and develop seed. Yet,
for others any sui generis system under TRIPS involves the allocation of
property rights over plant biodiversity and, therefore, its privatization.
All of them asked for an in-depth revision of TRIPS Article 27.3(b), either
to ensure the respect of farmers’ rights, or to forbid patents on life. In
this context, many groups and governments pointed to the achievements
that developing countries had obtained under the CBD. These groups
started to point to the contradictions between TRIPS and the CBD in order
to influence the outcome of the revision of TRIPS Article 27.3(b) in 1999
and the revision of the whole TRIPS in 2000. Perhaps the most known
of such analysis was that provided by GAIA/GRAIN in 1998, which is
summarized in Table 5.
When 1999 arrived, the review of TRIPS Article 27.3(b) was very
high up on the agenda. Countries entered the process with many
different proposals. Some official positions (like those of Jamaica, Sri
Lanka, Tanzania, Uganda, Zambia and the LDCgroup) proposed that
TRIPS should incorporate a provision stating that patents must not be
granted without prior informed consent of the country of origin, as
required under the CBD; others (like Kenya and Venezuela) asked for
the introduction of protection of indigenous knowledge and farmers’
rights; others (the LDC) asked for the exceptions of patentability to be
extended to all naturally occurring plants and animals, and their parts or
to microbiological processes (as proposed by SADC). The African group
held the strongest position by asking that the review should clarify
that plants, animals, micro-organisms, their parts and natural processes
cannot be patented—which would make patents on life illegal under
international legislation [44].
The proposals from developing countries could not be more
unacceptable to developed countries. Developing countries were firm,
though, and, in fact, they were so firm onWTO issues that they forced the
failure of the 1999 Seattle WTO Millennium Ministerial Meeting, which
finished without any agreement on Article 27.3(b). Consequently, only
30 per cent of WTO developing-country members implemented TRIPS
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Article 27.3(b) by the time their deadline materialized on 1 January
2000 [44]. Under the shock of Seattle, WTO did not push strongly
for the review of Article 27.3(b)—neither for the whole review of
TRIPS, due for 2000. TRIPS focused international attention again when
pharmaceutical giants pressed the US government to restrain South
Africa from importing royalty-free anti-AIDS medicines from India and
Brazil, which do not grant patents on pharmaceuticals. Access to cheap
patented medicines was the highest TRIPS-related issue at the Doha WTO
Ministerial Meeting of November 2001. The Doha Meeting decided to
continue with the discussions on Article 27.3(b) [45].
6.4. Beyond TRIPS, or TRIPS-plus
While international and national NGOs and governmental organizations
focused their attention on the discussions around the CBD and
TRIPS/WTO, the US, EU and Japan were busy establishing bilateral,
regional and subregional trade, investment, aid, science and technology
agreements that contain provisions on IPRs that are beyond TRIPS’
requirements (named as TRIPS-plus) [46]. After all, TRIPS is about the
minimum standards that countries have to implement to avoid non-
tariff barriers to trade. TRIPS-plus agreements include the Cotonou
Agreement between the EU and African, Caribbean and Pacific (ACP)
countries, which forces ACP countries to grant patents to biotechnology
inventions, and the currently negotiated Free Trade Area of the
Americas, where the US wants no exclusions for plants and animals
from patent law. GRAIN and the South Asia Network for Food, Ecology
and Culture (SANFEC) denounce these agreements for undermining
democracy as they involve only key ministers; push countries to adopt
political decisions that should be taken by parliaments; include pre-
negotiated dispute settlement processes even less transparent than
those of the WTO; and allow developed countries to impose draconian
conditions out of sight of their public opinion [46].
7. The Implications of UNCLOS, TRIPS and CBD for
Coastal Developing Countries
UNCLOS and the CBD entered into force in the first half of the
1990s. In contrast, as seen above, by June 2001 only 30 per cent of
developing countries had implemented provisions of TRIPS as they affect
biodiversity. So, while the first impacts of UNCLOS and the CBD have
already been felt, those arising from the effective addition of TRIPS are
subject to (informed) speculation. Furthermore, neither TRIPS nor the
CBD are written in stone: the review of Article 27.3(b) is ongoing and
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the CBD is being developed through voluntary guidelines and protocols.
Therefore, States still have some manoeuvring space to build national
legislations that best suit their peoples’ interests regarding biodiversity.
7.1. Countries’ actions to regulate access and benefit sharing
(ABS)
Since the CBD entered into force, many countries and international
organizations have established several measures to ensure their
participation in the benefits arising from the exploitation of their genetic
resources. These mechanisms have included the setting of governmental
(or regional) policies and legislations, the drawing of contracts
between users and providers, and codes of practice and voluntary
commitments14.Countries and supranational organizations that have
developed legislations on ABS include the Andean Community, the
ASEAN community (inspired by the Philippines), the Organization for
African Unity (OAU), India and Brazil15.
Current regimes on ABS share similar elements, although each
regime is unique. One such element is the need for a Prior Informed
Consent (PIC). The access-seeking party must inform in advance
the provider of genetic resources about the objectives, the economic
and the environmental implications of his or her intended actions.
Such information must be made understandable to indigenous or local
communities involved, if any. The CBD Draft Bonn Guidelines on Access
to Genetic Resources and Fair and Equitable Sharing of the Benefits
Arising out of their Utilization encourage countries to inform, consult
and take into account the opinion of indigenous and local communities
in their decisions on granting access. Whether this opinion is binding
depends on national legislations.
Once the PIC is obtained, access is provided on mutually agreed
terms establishing the conditions under which this access is granted
and the conditions for the sharing of the benefits. Established benefit-
sharing practices vary from country to country, and from contract to
contract, but they often include monetary and non-monetary measures.
Monetary measures include initial payments, labour, milestones and,
if the accessed genetic resources and associate knowledge reach
commercialization, a share on the royalties.
Non-monetary measures involve range from the setting up of
laboratory facilities to the training of national scientists in the country
14For a short and clear analysis of existing tools to regulating ABS, consult Seiler
A. and Dutfield G. (2002): Regulating Access and Benefit Sharing, Biotechnology
and Development Monitor 49: 3-7, March 2002. Available at http://www.
biotech-monitor.nl/4902.htm.
15For a compilation of these access legislations, visit http://www.grain.org/
brl/abs-brl-en.cfm.
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where the research will be conducted. It is here that States can negotiate
their preferential conditions of access to the technology incorporating
the genetic resources they provide. UNCLOS provisions on the rights
of coastal countries over scientific research in its EEZ (see above) are, in
fact, stronger than those of the CBD. Some countries distinguish between
academic and commercial objectives with regard to mutually agreed
terms for access. However, as illustrated by research on antitumour
marine agents, the distinction between public and private research can
be highly questionable.
As a result of the CBD, Material Transfer Agreements (MTAs)
have become a routine in the exchange of genetic resources. MTAs
are contracts that specify the conditions under which access to, and
authorized use of, a biological sample is provided, including the
conditions under which IPRs can—or cannot—be obtained for them.
For example, the exchange of carp and tilapia germplasm within the
International Network on Genetics in Aquaculture (INGA) is conducted
under MTAs [37].
Countries are not obliged to provide access to their genetic resources.
Australia, for example, has closed its hugely wealthy waters to foreign
researchers [17]. Therefore, companies interested in accessing and
developing active agents from the organisms of Australia’s Great Reef
Barrier (and from the rest of the countries’ coral reef systems) need to do
so through contact with national institutions like the Australian Institute
of Marine Sciences (AIMS).
7.2. The impact of the CBD on bioprospectors and in patent
offices
Four of the main marine bioprospecting teams and experts on the
development of marine antitumour agents identified in the course of this
research were contacted and their views on the impact of the entry into
force of the CBD were elicited. In general, bioprospectors feel—some
of them bitterly—that access to marine biodiversity, especially marine
invertebrates, is increasingly difficult. John Faulkner even wonders
whether the important increase in the number of papers reporting
studies on marine microorganisms is due to these access restrictions. An
interviewed expert even mentioned one case of corruption at the highest
government level as a barrier to access. The CBD is not the only driving
force behind bioprospectors’ ABS deals with developing countries in
order to access their marine biodiversity. The US National Cancer
Institute (NCI), the main public funder of the research on antitumour
agents, had a policy on the rights of the countries of origin, which was
prior to the entry into force of the CBD—which the US has not signed.
Indeed, in the absence of evidence of ABS documentation, no active agent
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Box 4
Access and Benefit Sharing: Pescanova and PharmaMar
PharmaMar is an ambitious Spanish bioprospecting company,
with offices in Madrid and Boston. It is about to launch an anti-cancer
compound, ET-743, in the market. It also has many other promising
antitumour agents at several stages of the R& D pipeline. PharmaMar
expects to earn US$1 bn from the sales of ET-743 alone.
PharmaMarwas founded by Jose´ Fernandez Souza-Faro, chairman
of Zeltia (PharmaMar’s parent company) in 1986 [18]. Zeltia had been
funded by Jose´ Ferna´ndez Lopez, a businessman from Galicia, Spain,
who also funded Pescanova, which today owns the world’s largest
private fishing fleet. Pescanova and Zeltia suscribed to an agreement
under which each Pescanova vessel has an expert biochemist on
board. This biochemist reviews and collects the organisms that,
entangled in fishing nets, get to vessels. By July 2000, this system had
been in place for about 10 years and had resulted in an investment of
more than US$53 mn [47].
However, when interviewed, PharmaMar staff are reluctant to
talk about the Pescanova-PharmaMar connection. Furthermore, they
insisted that, while having scientists on board fishing vessels could
be useful, the company is focusing on conducting targeted scuba-
diving collection in partnership with national organizations the world
over—including Africa, Asia and the US. PharmaMar uses its partner
organizations’ vessels to perform these collections, and tends to avoid
inhabited areas in order to avoid pollution—and perhaps also ABS
complications. PharmaMar staff claim that the company is closely
monitoring the CBD, and, in particular, the Bonn Draft Guidelines,
and that it intends to publicly launch a statement on its corporate
ABS policy soon. But then, why is its staff so reluctant to clarify the
company’s relation with Pescanova?
is allowed to proceed down the regulatory pathway16.
According to PharmaMar scientific staff, even patent offices are
asking for evidence of access and benefit-sharing agreements in order
to give course to any patent application involving genetic resources—
as has been called for by developing countries’ governments within the
review of TRIPS Article 27.3(b) and also by working groups at the CBD.
The main reason for this move at patent offices, though, is to avoid
the uncertainty stemming from the fact that some genetic resources are
found in more that one country.
16Personal communication from the Head of Biodiversity, PharmaMar, June 2002.
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7.3. Reality check on fairness and equity
The CBD compromise on access in exchange for the fair and equitable
sharing of the benefits (ABS) has created an entirely new market where
biodiversity-rich developing countries compete to attract the interest,
money and technology of developed countries’ corporations. This
market is fuelled by “a relatively small number of highly motivated
persons who have made benefit-sharing and access to genetic resources
their primary professional vocation”—biotrade brokers.
Since the CBD was negotiated, an enormous amount of literature
has been written on the subject. Nevertheless, when GAIA and GRAIN
investigated the real benefits accrued to local communities, they found
out that, to date, there is very little to show in new and substantial
benefits being accrued by the South, in general, or by local communities
and indigenous peoples, in particular [17].
There is, in fact, very little information on what countries (and
indigenous and local communities) are getting from ABS agreements,
since this is sensitive commercial information: biotrade brokers often
disclose only selected aspects of ABS agreements, out of context. This
secrecy fuels competition among biodiversity-rich countries, mainly
when they share some or many species—unless such countries decide
to promote a co-operative approach to ABS negotiations. Furthermore,
whether promised payments deriving from royalties actuallymaterialize
depends on whether the (patented) technology successfully reaches the
market. However, there are some indicators that “fair and equitable” are
often not among the main concerns in ABS deal negotiations.
Good examples of this are the ABS agreements negotiated by Diversa,
a US company specialized in accessing, patenting and developing
bacterial enzymes. Diversa’s agreement with Mexico’s National
Autonomous University (UNAM) allows it to access the country’s
microbial biodiversity in exchange of equipment valued at US$5,000,
technical training related to the collection and categorization of samples,
US$50 per sample collected, and royalties on net sales of products
developed frommaterials collected. The level of royalties will vary from
0.5 per cent in the case of pharmaceuticals to 0.3 per cent in the case of
other products.
It turned out that Diversa’s agreement with the Yellowstone National
Park to access the park’s extremophile bacteria, challenged in court by
a US NGOs’ coalition, included 10 per cent royalty transfer: the US got
twenty times more than Mexico [48].
There is no indication that marine bioprospecting agreements are
fairer and more equitable than their terrestrial equivalents; indeed, there
are some indications that they are not. Australia is a case in point. As
mentioned above, Australia has closed its waters to foreign scientists. A
developed country, Australia is building its own marine biotechnology
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capacity. For example, AIMS has established the Marine Bioproducts
group, which aims to discover new marine molecules of commercial
use in many areas. AIMS itself co-owns a patent with ICI Australia
on a sunscreen produced from reef organisms (US Patent 5,637,718).
AIMS has signed a biotechnology benefit-sharing agreement with the
State of Queensland. The agreement does not deal with AIMS’ access to
Australian biodiversity, which can only be prevented on environmental
grounds. However, it provides the certainty required to secure industrial
partners for AIMS’ R&D—which need not be of Australian origin.
According to AIMS, non-monetary benefits covered by the agreement
include documentation of biodiversity to aid better management,
capacity building in this kind of R&D, opportunity for intellectual
property development in new discoveries, and the development of
a new, innovative, sustainable resource-based biotechnology industry.
Monetary benefits include the transfer of 1.5 per cent of net profit
received by AIMS as a result of R&D on biological samples obtained
from Queensland—not of the net profits the samples generate. This is
very ambiguous, and it can vary enormously, depending on the terms
under which AIMS licenses its technologies. Altogether, wealthy and
developed Queensland has lost control over its marine biodiversity,
which AIMS gets to scan for a pittance17.
Perhaps an unexpected effect of the entry into force of the CBD is the
introduction of a new ethos in the conservation policies of developed
countries. The conservation of protected areas had traditionally
been undertaken by the public sector and financed by public money.
Suddenly, protected areas have gained commercial value, which is often
perceived by the managers of those areas as a source of complementary
income to finance their own scientific activities. Accordingly, they
proceed to sign ABS agreements with the private sector that alienate
the rights of the public over them. The slope between selling access to
conserve and conserving to sell access might be a slippery one, though.
7.4. TRIPS, CBD and State control over biodiversity
It may be argued that the ABS scene will improve with time, as
countries gain more experience, ABS guidelines are implemented, and
the technologies covered by ABS agreements start to deliver royalties. In
contrast, the pressure on developing countries to grant patents over their
genetic resources is forceful and immediate.
The CBD obliges each member State to acknowledge and respect IPRs
on the technologies and inventions derived from its genetic resources
17The presentation of the Biotechnology Benefit Sharing Agreement between AIMS
and the State of Queensland is available at http://www.aims.gov.au/pages/
about/corporate/bsa-aims-qldgov.html.
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if these are obtained through a prior informed consent and terms
for the sharing of resulting benefits are mutually agreed—even if the
deal is reached by another member State. Consequently, this would
force countries to acknowledge IPRs on the technologies and inventions
based on genetic resources under their sovereignty—no exceptions are
mentioned.
Under TRIPS, countries are also obliged to accept IPRs over all
products and technologies, including microorganisms. Until Article
27.3(b) is reviewed, countries may exclude plants and animals from
patenting, but there are strong pressures to lift these exceptions. The
ever-widening scope of international patenting practices and TRIPS-plus
bilateral, subregional and regional agreements also add to the pressure
on developing countries to progressively accept private ownership over
their genetic resources, regardless of whether they granted access to
them or not. At that moment, countries will be left with very little
options to conserve and sustainably develop biodiversity, and so will
their indigenous and local communities.
Developing countries must react strongly to avoid such appropria-
tion of the biodiversity—at least in their territories. Action may include:
1. Taking advantage of the manoeuvring space left by the interpreta-
tion of TRIPS: This would include establishing IPR regimes that, inter
alia, define ‘discovery’ in a way that prevents the patenting of any
substance already existing in nature; exclude plants and animals of
patentability; include stringent novelty requirements that include
prior oral disclosure anywhere in the world; and do not allow for
broad claims over inventions [49]. However, these measures can
be short-lived as pressure to adopt developed countries’ standards
increase.
2. Establishing rights regimes ensuring the inalienability of indige-
nous peoples’ and local communities’ rights to access, conserve and
sustainably develop biodiversity: Such rights should be a priori and
the rights of other users of genetic resources would be subordinated
to them—exactly the opposite of what is happening within CBD ne-
gotiations. There are conflicting opinions on whether the rights of
indigenous peoples and local communities should be established
under the WTO, which deals with trade. WTO has the advantage
that, through cross-retaliation, sanctions are enforceable; in contrast,
the undemocratic dispute settlement and arbitration mechanisms at
WTO are a disadvantage, as they could establish that measures to
protect indigenous peoples and local communities are barriers to
trade. A further problem with TRIPS is that it deals with property
rights, and property is alienable and can be bought and sold. There-
fore, the rights of indigenous peoples and local communities should
be established outside TRIPS and must be above and beyond WTO
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jurisdiction, just as human rights are—nobody can point to the en-
forcement of human rights as a trade barrier.
3. Joining the African Group position that the review of TRIPS
Article 27.3(b) should clarify that plants, animals, micro-organisms,
their parts and natural processes cannot be patented: Developing
countries may be worried by the fact that a ban on patents on plants,
animals, micro-organisms, their parts and natural processes would
automatically threaten their expectations under ABS agreements.
However, forbidding patents on life does not mean that incentives
for the scientific development of genetic resources are not urgently
needed. In fact, many scientists wonder whether the explosion of
patents in biotechnology fosters innovation or, instead, stifles it.
The patent system is showing its limitations in the case of marine
antitumour development—where the time required for R&D is
much more than that provided by patent protection [22].
8. The Implications of TRIPS and the CBD for
Coastal Communities
8.1. TRIPS, coastal indigenous peoples and local communities
TRIPS has no explicit say about indigenous peoples or local communities,
coastal or otherwise. Implicitly, it ignores them and hence it facilitates
the appropriation of their biodiversity and associated knowledge. For
example, US law, unlike the law in force in most other countries, does
not consider that ‘novelty’ is lost when an invention has been divulged
outside the US by non-written means, such as public use and sale [49].
Once developing and less developed countries have established
their IPR systems, US corporations are likely to put pressure on these
countries to accept the patents they have been granted at home. In fact,
some TRIPS-plus agreements already entail the acknowledgement of US
patents in partner countries.
Furthermore, there is a trend towards the development of
supranational patent offices—currently it is national governments who
grant or refuse IPRs. The EU is designing a European Patent that would
be enforced in all its member States. Nobody knows where this trend
will lead to, but the integration of patent authorities is more likely to
suit the interests of transnational corporations than those of much less
powerful indigenous and local communities.
The high visibility of the debate on the ownership of biodiversity
and the highly publicized conflict between the CBD and TRIPS has
forced the IPR establishment to take indigenous and local communities
knowledge systems into account. Its main effort to do so has beenWIPO’s
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Intergovernmental Committee on Intellectual Property and Genetic
Resources, Traditional Knowledge and Folklore.
The Intergovernmental Committee has discussed intellectual prop-
erty issues in the context of access to genetic resources and benefit-
sharing; protection of traditional knowledge, whether or not associated
with those resources; and the protection of expressions of folklore [50].
WIPO’s effort aims to include TEKS into (the logics of) IPR regimes. Such
‘soft’ IPR systems would then be incorporated into TRIPS, and, hopefully,
put an end to the debate on the contradictions between TRIPS and the
CBD. The real danger of this is that in these discussions TEKS are defined
in the light of IPRs, rather than in the light of their own histories and
needs.
Furthermore, this move transposes the assumptions underlying
industrial IPR regimes—the common good is favoured by the monopoly
of knowledge, and that such monopoly can be bought and sold—to
societies relying on the options arising from the direct use of biodiversity,
where knowledge is spread and exchange, vital for survival.
8.2. The CBD, indigenous peoples and coastal communities
The CBD establishes that the definition and protection of the rights of
indigenous and local communities are subject to national legislation.
As seen above, current work within the CBD (a) stresses indigenous
and local communities’ participation in ABS negotiations, rather than
their own contribution to biodiversity conservation; and (b) grants WIPO
authority in defining the rights of indigenous and local communities,
instead of defining them aside of IPRs.
The definition of indigenous and local communities’ rights in the
IPR blueprint may hide a trap: limiting such rights to those groups’
knowledge of particular uses of particular species. Furthermore, it
reduces knowledge of biodiversity to knowledge of single species.
What should be protected, though, are the rights of indigenous and
local communities to exert control on the biodiversity they depend on—
which, in one form or another, is a result of biocultural diversity and
associated TEKS. This is especially relevant for the indigenous and
coastal communities who do not exploit the invertebrates targeted by
bioprospectors but who rely on the ecosystems that hold such species.
It is also relevant for First Nations in whose territories spawn
the wild species of salmon necessary for the aquaculture industry.
The contribution of indigenous peoples’ and coastal communities’
traditional management systems to biodiversity conservation is
increasingly acknowledged. Therefore, rights of coastal and riverside
indigenous and local communities to continue conserving biodiversity
should be protected under the CBD.
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Such rights should be a priori rights, collective and unalienable.
Their enforcement should ensure communities’ control over the
biodiversity they rely on and should promote their further development.
Much thinking has gone into how such rights systems would look
and how they would be integrated into the international regulatory
framework defining control over biodiversity. Biocultural diversity does
not facilitate the task, but makes it more challenging.
9. Conclusions and Recommendations
9.1. A resume´ of findings and conclusions
From the facts above, it can be concluded that:
• Coastal communities have been largely marginalized in the
international debates on the control over biodiversity.
• Scientific knowledge of marine biodiversity is incomplete and
scattered. This ignorance applies both to our capacity to develop
the 20,000 marine substances, and to assess and forecast the impact
of human activities.
• Today’s coastal marine biodiversity is largely a result of the
traditional management systems, an expression coastal indigenous
peoples and local communities’ traditional ecological knowledge
systems (TEKS).
• Coastal communities’ TEKS also include the use of marine
biodiversity to suit many needs other than food, including
medicinal use. Such uses, though, remain largely unpublicized and
poorly understood.
• The pharmaceutical industry seems to be less reliant on indigenous
and local communities’ knowledge of the medicinal use of marine
biodiversity than on local use of medicinal plants.
• The prospects for local communities’ ability to benefit from
sustainable fisheries on marine molecule producing organisms
are shaped by industry’s use of professional scuba divers and
its progressive shift towards marine micro-organisms and genetic
engineering as a means to find and obtain new molecules.
• The aquacultural industry is proceeding to domesticate cultivated
species. However, the wild fish populations that hold the genetic
resources necessary for this domestication are being eroded by
many causes, including aquacultural operations themselves. This
contradiction has led to an increase in the ex situ conservation of
fish germplasm and to the increasing application of IPRs over fish
genetic diversity.
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• The CBD establishes three sets of rights:
. the sovereign rights of States over biodiversity;
. the rights of the holders of industrial technology, who enjoy
IPRs and may keep their information confidential; and
. the rights of the holders of TEKS, which are subject to national
legislation, and whose knowledge must be made publicly
available.
• Both TRIPS and the CBD are evolving processes. The review of
Article 27.3(b) is still open, as are the CBD provisions, including
those relative to the rights of indigenous and local communities.
• Current work within the CBD (a) stresses indigenous and local
communities’ participation in ABS negotiations, rather than their
own contribution to biodiversity conservation; and (b) grants
WIPO authority in defining the rights of indigenous and local
communities, instead of defining them aside of IPRs.
• According to industry sources, one of the demands of thoseworking
for the rights of indigenous and local communities in developing
countries, that the granting of patents be subject to evidence of PIC
of the country of origin, is now a practice in some patent offices.
This is a defensive move aiming to prevent patent challenges by
countries holding the genetic resources or associated knowledge
contained in the patents.
• The pressures for developing and least developed countries to
allow the patenting of genetic resources and living beings are so
strong, both under TRIPS and under TRIPS-plus agreements, that
countries could find, in the mid-term, that the sovereignty of their
biodiversity has been appropriated through IPRs.
• To avoid this, countries need to establish rights regimes ensuring the
inalienability of indigenous peoples’ and local communities’ rights
to access, conserve and sustainably develop biodiversity. Such
rights should be a priori rights, collective and unalienable, and the
rights of other users of genetic resources and biodiversity would be
subordinated to them.
• The CBD offers a space for countries to provide such rights—
provided that they are established independently from the frame
of IPRs, as is now happening.
• The rights of indigenous and coastal communities who have
maintained and preserved marine biodiversity through their
traditional management systems should be protected under the
CBD.
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9.2. A role for ICSF?
This report is a first attempt to look at issues in marine biodiversity from
a perspective that is new for the International Collective in Support of
Fishworkers (ICSF)—that of the use of marine biodiversity for purposes
other than food; or, in other words, that of the control over coastal
communities’ intellectual knowledge of marine biodiversity.
• A first conclusion is that the issue of the rights over resources
deriving from knowledge is not such a new issue to ICSF, which,
as an organization, has been fighting, for many years now,
for the rights of coastal communities to their traditional fishing
grounds. ICSF has been decisive in the increasing recognition of
the contribution of coastal communities’ traditional management
systems to the marine biodiversity we all enjoy.
• One of the main purposes of this research exercise was to look at the
richness of coastal communities’ TEKS on marine biodiversity. The
main finding is that these systems remain largely unpublicized and
poorly understood. In the face of the current hype on knowledge
misappropriation—either mediated by ABS agreements or not—
ICSF should ensure that any effort to fill this gap goes beyond
mere documenting to providing active support to the further
development of TEKS, towards better management of coastal and
marine resources and towards strengthening traditional medicinal
systems.
• ICSF can build its political analysis and its capacity-building
activities around the issues concerning the knowledge and
maintenance of biodiversity, at species and ecosystem levels, for
food or for any other use—in a way that enriches, rather than
modifies, its current programmes.
• ICSF has much to gain from monitoring the CBD and TRIPS and
joining organizations working to promote community rights over
biodiversity. In this work, ICSF should make sure it is linked to real
stakeholders and/or their representatives. It should also always
critically assess whether its actions—and those of its partners—
promote the privatization of biodiversity, albeit in an indirect way.
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